Phio Pharmaceuticals (PHIO) Enterprise Value (2011 - 2026)
Phio Pharmaceuticals' (PHIO) quarterly Enterprise Value came in at -$17.0 million in Q1 2026, down 28.26% YoY from -$23.7 million in Q1 2025, and up 19.02% on a QoQ basis from -$21.0 million in Q4 2025.
Phio Pharmaceuticals (PHIO) Enterprise Value (2011 - 2026) Analysis & Trends
Phio Pharmaceuticals (PHIO) has 16 years of Enterprise Value data on file, last reported at -$17.0 million in Q1 2026.
- Quarterly Enterprise Value fell 28.26% year-over-year to -$17.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$17.0 million (down 28.26% YoY) and the FY2025 annual result came in at -$21.0 million, down 290.77% from the prior year.
- Enterprise Value improved to -$17.0 million in Q1 2026, from -$21.0 million in the prior quarter.
- In the past five years, Enterprise Value ranged from a high of -$4.7 million in Q2 2024 to a low of -$21.0 million in Q4 2025.
- A 5-year average of -$11.6 million and a median of -$10.8 million in 2025 frame the typical range for Enterprise Value.
- Annual changes were most pronounced in 2024 — Enterprise Value soared 58.45% — and 2025, when it sank 290.77%.
- Tracing PHIO's Enterprise Value over 5 years: stood at -$11.8 million in 2022, then rose by 27.93% to -$8.5 million in 2023, then soared by 36.61% to -$5.4 million in 2024, then slumped by 290.77% to -$21.0 million in 2025, then climbed by 19.02% to -$17.0 million in 2026.
- The last three Enterprise Value figures came in at -$17.0 million (Q1 2026), -$21.0 million (Q4 2025), and -$10.7 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Enterprise Value (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | -7.85 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | -7.99 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | -5.18 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | -5.14 Bn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | -5.10 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | -3.31 Bn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | -1.16 Bn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 2.12 Bn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -18.39 Bn |
| 10 | Phio Pharmaceuticals | 14.06 Mn | 14.06 Mn | - | -13.00 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -13.00 Mn |
| Mar 31, 2026 | -17.03 Mn |
| Dec 31, 2025 | -21.03 Mn |
| Sep 30, 2025 | -10.71 Mn |
| Jun 30, 2025 | -10.78 Mn |
| Mar 31, 2025 | -13.28 Mn |
| Dec 31, 2024 | -5.38 Mn |
| Sep 30, 2024 | -5.39 Mn |
| Jun 30, 2024 | -4.70 Mn |
| Mar 31, 2024 | -6.48 Mn |
| Dec 31, 2023 | -8.49 Mn |
| Sep 30, 2023 | -8.41 Mn |
| Jun 30, 2023 | -11.31 Mn |
| Mar 31, 2023 | -9.04 Mn |
| Dec 31, 2022 | -11.78 Mn |
| Sep 30, 2022 | -14.48 Mn |
| Jun 30, 2022 | -18.02 Mn |
| Mar 31, 2022 | -20.46 Mn |
| Dec 31, 2021 | -24.06 Mn |
| Sep 30, 2021 | -26.53 Mn |